Fernando Cwilich Gil, Individually and on Behalf of Ruse Laboratories v. Benjamin Paul Gleitzman, Replicant Solutions, Inc.

CourtCourt of Chancery of Delaware
DecidedMarch 4, 2024
DocketC.A. No. 2022-0173-BWD
StatusPublished

This text of Fernando Cwilich Gil, Individually and on Behalf of Ruse Laboratories v. Benjamin Paul Gleitzman, Replicant Solutions, Inc. (Fernando Cwilich Gil, Individually and on Behalf of Ruse Laboratories v. Benjamin Paul Gleitzman, Replicant Solutions, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fernando Cwilich Gil, Individually and on Behalf of Ruse Laboratories v. Benjamin Paul Gleitzman, Replicant Solutions, Inc., (Del. Ct. App. 2024).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

FERNANDO CWILICH GIL, ) individually and on behalf of RUSE ) LABORATORIES CORP., ) ) Plaintiff, ) v. ) C.A. No. 2022-0173-BWD ) BENJAMIN PAUL GLEITZMAN, ) REPLICANT SOLUTIONS, INC., ) Defendants, ) ) and ) RUSE LABORATORIES CORP., ) ) Nominal Defendant. ) FINAL REPORT Final Report: March 4, 2024 Date Submitted: February 2, 2024 Andrew S. Dupre, Brian R. Lemon, and Stephanie H. Dallaire, MCCARTER & ENGLISH, LLP, Wilmington, Delaware; Attorneys for Plaintiff Fernando Cwilich Gil and Nominal Defendant Ruse Laboratories Corp. Michael A. Weidinger and Megan Ix Brison, PINCKNEY, WEIDINGER, URBAN & JOYCE, LLC, Wilmington, Delaware; OF COUNSEL: Elizabeth Sandza, SANDZA LAW, PLLC, Washington, D.C.; Attorneys for Defendant Benjamin Paul Gleitzman. Elena C. Norman, Daniel M. Baker, and Alex B. Haims, YOUNG CONAWAY STARGATT & TAYLOR, LLP, Wilmington, Delaware; OF COUNSEL: Ben Au, ORRICK, HERRINGTON & SUTCLIFFE LLP, Santa Monica, California; Ariel Winawer, ORRICK, HERRINGTON & SUTCLIFFE LLP, San Francisco, California; Sarah Shyy, ORRICK, HERRINGTON & SUTCLIFFE LLP, Irvine, California; Attorneys for Defendant Replicant Solutions, Inc.

DAVID, M. Plaintiff Fernando Cwilich Gil (“Plaintiff”) and defendant Benjamin

Gleitzman are the co-founders and sole directors, officers, and stockholders of

nominal defendant Ruse Laboratories Corp. (“Ruse” or the “Company”). In

February 2022, Plaintiff initiated this action, asserting claims against Gleitzman for

breach of fiduciary duty; seeking a declaration that a certificate of dissolution filed

on behalf of Ruse is void or invalid; and requesting the appointment of a receiver for

the Company.

In June 2023, Plaintiff filed a second amended complaint. The amended

pleading adds a claim against Gleitzman for breach of an assignment agreement

under which Gleitzman assigned his rights in “Company Inventions” to Ruse; a

claim against a new defendant, Replicant Solutions, Inc. (“Replicant”), for tortious

interference with that assignment agreement; and a request for declaratory relief

arising from those claims.

This final report resolves Gleitzman and Replicant’s (“Defendants”) motions

to dismiss those newly added claims as time-barred under the applicable statutes of

limitations. For the reasons explained below, I recommend that the Court dismiss

the tortious interference claim and otherwise deny the motions to dismiss.

1 I. BACKGROUND 1

A. Plaintiff and Gleitzman Assign Their Rights In Company Inventions To Ruse.

In 2014, Plaintiff Fernando Cwilich Gil and defendant Benjamin Paul

Gleitzman co-founded Ruse, a Delaware corporation, “to develop various

technology-based projects.” SAC ¶ 13. Plaintiff, “an artist and creative director

working with technology,” and Gleitzman, “a software engineer and manager,” are

each fifty percent stockholders of Ruse. Id. ¶¶ 15-16. Plaintiff serves as Ruse’s

CEO and President, and Gleitzman serves as Ruse’s Secretary. Id. ¶¶ 1, 26-27.

On April 6, 2014, Plaintiff and Gleitzman each executed a Confidential

Information and Invention Assignment Agreement (the “Assignment Agreement”)

in which they agreed that, while employed by the Company, they would disclose and

assign all rights in any patents to Ruse:

Assignment of Company Inventions. I agree that I will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby assign to the Company, or its designee, all my right, title and interest throughout the world in

1 The following facts are taken from the Corrected Verified Second Amended Complaint (the “Second Amended Complaint”) and the documents incorporated by reference therein. Corrected Verified Second Am. Compl. [hereinafter, “SAC”], Dkt. 67. See Freedman v. Adams, 2012 WL 1345638, at *5 (Del. Ch. Mar. 30, 2012) (“When a plaintiff expressly refers to and heavily relies upon documents in her complaint, these documents are considered to be incorporated by reference into the complaint[.]” (citation omitted)).

2 and to any and all Company Inventions 2 and all patent, copyright, trademark, trade secret and other intellectual property rights therein.

SAC, Ex. A [hereinafter, “Assign. Agt.”] § 4(d) (emphasis added). The Assignment

Agreement is governed by California law. Id. § 12(a).

B. Gleitzman Invents Technology While Working For Atomic and Replicant. The Complaint alleges that “in 2014 and 2015, Ruse did work for Atomic, a

venture capital fund and technology incubator, and its CEO Jack Abraham.” SAC

¶ 37. “In mid-2017, Gleitzman began exploring the possibility of Ruse again

working with Atomic on an outgoing robocalling technology project.” Id. ¶ 38.

“After seeking and obtaining [Plaintiff]’s consent, Gleitzman and Ruse began

2 The Assignment Agreement defines “Inventions” to include: discoveries, developments, concepts, designs, ideas, know how, improvements, inventions, trade secrets and/or original works of authorship, whether or not patentable, copyrightable or otherwise legally protectable[] [which] . . . includes, but is not limited to, any new product, machine, article of manufacture, biological material, method, procedure, process, technique, use, equipment, device, apparatus, system, compound, formulation, composition of matter, design or configuration of any kind, or any improvement thereon. Assign. Agt. § 4(c). “Company Inventions” are defined to include “any and all Inventions that [Gil or Gleitzman, respectively,] may solely or jointly author, discover, develop, conceive, or reduce to practice during the period of the Relationship, except as otherwise provided in Section 4(g) below.” Id. “Relationship” is defined as “[a]ny such employment or consulting relationship between the parties hereto, whether commenced prior to, upon or after the date of this Agreement . . . .” Id. § 1.

3 working on an Atomic company known as ‘Replicant.’” Id. ¶ 39. According to the

Complaint,

Gleitzman was not able to exploit the opportunity in Replicant alone, but rather required the use of Ruse’s resources, assets and frequent collaborators to help him develop Replicant’s code, design, content, product and brand. Ruse’s work for Atomic on Replicant was typical. [Plaintiff] focused mostly on the creative and product side, such as experimenting with how the technology could be used while refining its concept and design; Gleitzman worked primarily on code development and financial management. Gleitzman and [Plaintiff] also organized and recruited freelance coders to assist Gleitzman in code development for Replicant.

Id. ¶¶ 40-41. Plaintiff alleges that Ruse completed its work for Replicant without

executing a contract with Atomic or Replicant, expecting that “Gleitzman would

negotiate the best possible equity deal for Ruse.” Id. ¶¶ 42-43. But instead,

“Gleitzman secured a personal equity interest in Replicant in exchange for the work

performed by Ruse and accepted a salaried position as [Replicant’s] Chief Technical

Officer.” Id. ¶ 44.

In June and August 2017, Atomic filed with the United States Patent and

Trademark Office (“USPTO”) two provisional patent applications (the “Provisional

Applications”) based on technology developed in collaboration with Gleitzman (the

“‘038 Technology”). See SAC, Exs. C, D. Although Gleitzman developed the ‘038

4 Technology with Replicant, the Provisional Applications listed only Abraham as the

inventor and Atomic as assignee. Id. ¶¶ 48-49; see also id., Exs. C, D. 3

On June 22, 2018, Atomic filed a non-provisional patent application (the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Norgart v. Upjohn Co.
981 P.2d 79 (California Supreme Court, 1999)
Bernson v. Browning-Ferris Industries of California, Inc.
873 P.2d 613 (California Supreme Court, 1994)
Jolly v. Eli Lilly & Co.
751 P.2d 923 (California Supreme Court, 1988)
Saudi Basic Industries Corp. v. Mobil Yanbu Petrochemical Co.
866 A.2d 1 (Supreme Court of Delaware, 2005)
Mullen v. Alarmguard of Delmarva, Inc.
625 A.2d 258 (Supreme Court of Delaware, 1993)
CCS INVESTORS, LLC v. Brown
977 A.2d 301 (Supreme Court of Delaware, 2009)
In Re Tyson Foods, Inc. Consolidated Shareholder Litigation
919 A.2d 563 (Court of Chancery of Delaware, 2007)
Community Cause v. Boatwright
124 Cal. App. 3d 888 (California Court of Appeal, 1981)
SmithKline Beecham Pharmaceuticals Co. v. Merck & Co., Inc.
766 A.2d 442 (Supreme Court of Delaware, 2000)
Frombach v. Gilbert Associates, Inc.
236 A.2d 363 (Supreme Court of Delaware, 1967)
Ingres Corp. v. CA, INC.
8 A.3d 1143 (Supreme Court of Delaware, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
Fernando Cwilich Gil, Individually and on Behalf of Ruse Laboratories v. Benjamin Paul Gleitzman, Replicant Solutions, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fernando-cwilich-gil-individually-and-on-behalf-of-ruse-laboratories-v-delch-2024.